New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:56 EDTLCILannett decline on Connecticut probe seems overdone, says Roth Capital
After Lannett fell 17% following the disclosure that it had received subpoenas from Connecticut regarding the pricing of digoxin, Roth Capital does not expect the state to take any further action against the company. The firm does not believe that there has been any collusion on digoxin prices. It keeps a $45 price target and Buy rating on the shares.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:28 EDTLCISenate Health, Education, Labor & Pensions Committee to hold a hearing
The Subcommittee on Primary Health and Aging holds a hearing entitled, "Why Are Some Generic Drugs Skyrocketing In Price?" with President & CEO Vigodman of Teva Pharmaceutical and President & CEO Bedrosian of Lannett Company on November 20 at 1 pm. Webcast Link
November 17, 2014
16:56 EDTLCILannett announces retirement of Chief Compliance Officer Ernest Sabo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use